《新股消息》未盈利生科企和鉑醫藥遞上市申請
未盈利的內地生物製藥企業和鉑醫藥遞交上市申請,保薦人為摩根士丹利、美國銀行及中信證券。
初步文件顯示,和鉑醫藥從事研究及開發免疫與腫瘤疾病領域的新型及高度差異化抗體療法,截至2020年6月30日已有六個項目進入臨床階段。由於尚未有產品獲准進行商業銷售,因此該公司未從產品銷售產生任何收益,於2018年及2019年年度錄經營虧損3,460萬美元及6,750萬美元,並於今年上半年蝕4,840萬美元。
和鉑醫藥上月宣布,已完成1.03億美元C輪融資,該次融資由Hudson Bay Capital領投,碧桂園(02007.HK)碧桂園創投、奧博資本、高特佳投資集團、銳智資本等參投。招股資料顯示,GIC、國壽成達、聯想控股旗下正奇金融等,亦為公司上市前投資者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.